Prostate Cancer Excellence Forum

Prostate Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Neal Shore, MD, Carolina Urologic Research Center

Interview

Darolutamide Plus ADT and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

09/01/2022

Neal Shore, MD, shares insights about the recent FDA approval of darolutamide plus ADT and docetaxel for patients with metastatic hormone-sensitive prostate cancer and the data that led to this approval.

Neal Shore, MD, shares insights...

09/01/2022

Oncology

Videos

Enzalutamide Added to Testosterone Suppression Improves OS in Metastatic Hormone-Sensitive Prostate Cancer

07/21/2022

Ian Davis, MBBS, PhD, FRACP, FAChPM, discusses updated OS outcomes from the ENZAMET trial, exploring testosterone suppression plus either enzalutamide or a conventional non-steroidal anti-androgen in metastatic hormone-sensitive prostate...

Ian Davis, MBBS, PhD, FRACP,...

07/21/2022

Oncology

Videos

Dr Tward Discusses 2022 Anticipated Prostate Cancer Advancements Part 2

02/28/2022

In part two of this series, Dr Tward, MD, Huntsman Cancer Institute, discusses use of the Polaris test to prognosticate metastasis of men undergoing radiation therapy with prostate cancer, as well as ongoing efforts to further advance...

In part two of this series, Dr...

02/28/2022

Oncology

Jonathan Tward, MD, Huntsman Cancer Institute

Videos

Dr Jonathan Tward Discusses New and Upcoming Advancements for Prostate Cancer: Part 1

02/28/2022

In part one of this series, Dr Jonathan Tward, MD, Huntsman Cancer Institute, reviews ongoing efforts to further advance personalized treatment in the prostate cancer space.

In part one of this series, Dr...

02/28/2022

Oncology

Dr Chi, MD, Discusses Phase 3 MAGNITUDE, SPARTAN, and TITAN Study Results

02/17/2022

Kim Chi, MD, Vancouver Prostate Centre, Discusses Phase 3 MAGNITUDE study of niraparib as well as the SPARTAN and TITAN studies, presented at 2022 ASCO GU Meeting.

Kim Chi, MD, Vancouver Prostate...

02/17/2022

Oncology

Videos

Dr Tagawa Discusses Study Results of Actinium J591 for mCRPC

06/22/2021

Scott Tagawa, MD, MS, FACP, discusses the background and findings of a phase 1 study on the use of a PSMA-targeted radionuclide therapy for patients with mCRPC.

Scott Tagawa, MD, MS, FACP,...

06/22/2021

Oncology

Interview

Dr Schweizer Talks Concordance of DDR Mutations in Paired Primary, Metastatic Prostate Cancer Samples

06/15/2021

Michael Schweizer, MD, Seattle Cancer Care Alliance, discusses a prostate cancer study that was presented at the 2021 ASCO Annual Meeting.

Michael Schweizer, MD, Seattle...

06/15/2021

Oncology

Videos

Dr Agarwal Discusses Final Analysis Results of the TITAN Study - Part 1

06/15/2021

In part one of this video series, Neeraj Agarwal, MD, discusses HRQoL and patient-reported outcomes at final analysis of the TITAN study being presented at the virtual 2021 ASCO Annual Meeting.

In part one of this video...

06/15/2021

Oncology

Videos

Dr Tagawa Talks Final Analysis Results of the TITAN Study

06/08/2021

Scott Tagawa, MD, MS, FACP, provides commentary on the results of TITAN, a phase III study of apalutamide in patients with mCSPC receiving androgen deprivation therapy.

Scott Tagawa, MD, MS, FACP,...

06/08/2021

Oncology

Interview

Dr Labanca Talks Use of Non-Canonical AR Signaling, Ketone Body Fuel in CRPC

05/03/2021

Estefania Labanca, PhD, discusses data on CRPC progression and the use of non-canonical AR signaling and ketone body fuel which were presented at the AACR Annual Meeting.

Estefania Labanca, PhD,...

05/03/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology